ACA
GCVRZ

Atlas Capital Advisors’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Atlas Capital Advisors’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-280
Closed -$145 – 720
2019
Q2 		$145 Hold
280
– – ﹤0.01% 651
2019
Q1 		$126 Hold
280
– – ﹤0.01% 560
2018
Q4 		$134 Hold
280
– – ﹤0.01% 558
2018
Q3 		$146 Hold
280
– – ﹤0.01% 536
2018
Q2 		$138 Hold
280
– – ﹤0.01% 500
2018
Q1 		$118 Buy
+280
New +$113 ﹤0.01% 514

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Atlas Capital Advisors's GCVRZ Position: Q3 2019 in Review

Atlas Capital Advisors sold out of Sanofi Contingent Value Rights (GCVRZ) in Q3 2019, closing a stake of 280 shares — an estimated $145 sold.

Atlas Capital Advisors first reported a position in GCVRZ in Q1 2018 and held it in 6 quarters. The position peaked at $146 in Q3 2018. 103 funds tracked by Wall St. Rank hold GCVRZ as of Q3 2019.

  • Atlas Capital Advisors reported no remaining Sanofi Contingent Value Rights position as of Q3 2019 after selling out during the quarter.
  • Atlas Capital Advisors sold 280 Sanofi Contingent Value Rights shares in Q3 2019, an estimated $145.
  • Atlas Capital Advisors first reported a position in Sanofi Contingent Value Rights in Q1 2018 and held it in 6 quarters.
  • Atlas Capital Advisors's Sanofi Contingent Value Rights position peaked at $146 in Q3 2018.
  • 103 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q3 2019.

Based on Atlas Capital Advisors's 13F filing for Q3 2019, filed 1 Nov 2019.